maridebart cafraglutide (AMG 133) / Amgen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
maridebart cafraglutide (AMG 133) / Amgen
2022-002470-86: A study of AMG 133 in adults with obesity or overweight, with or without type 2 diabetes

Not yet recruiting
2
570
Europe, RoW
AMG 133, Solution for injection
Amgen Inc., Amgen Inc
Overweight and Obesity, Obesity, Diseases [C] - Nutritional and Metabolic Diseases [C18]
 
 
NCT05669599 / 2022-002470-86: Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

Active, not recruiting
2
592
Europe, Canada, Japan, US, RoW
Maridebart Cafraglutide, AMG 133, Placebo
Amgen, Amgen Inc
Obesity, Overweight, Type 2 Diabetes Mellitus
10/24
01/26
NCT06660173: A Study of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus (T2DM)

Recruiting
2
350
Europe, Japan, US, RoW
Maridebart Cafraglutide, AMG 133, Placebo
Amgen
Type 2 Diabetes Mellitus (T2DM)
11/25
07/26
NCT06352892: A Study to Evaluate AMG 133 in Chinese Participants With Obesity or Overweight

Completed
1
20
RoW
Maridebart Cafraglutide, AMG 133
Amgen
Obesity
08/24
08/24

Download Options